OncoGenex Pharma (OGXI) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mailGet Alerts OGXI Hot Sheet
Join SI Premium – FREE
OncoGenex Pharma (NASDAQ: OGXI) reported Q4 EPS of ($0.26), $0.04 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $5.7 million versus the consensus estimate of $4.3 million.
For earnings history and earnings-related data on OncoGenex Pharma (OGXI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AIR Global sets first-ever dividend, $100M buyback amid business, cash strength
- GeoPark Q3 2026 output rises 2.6% on Argentina growth
- Westamerica Bancorp. (WABC) Tops Q3 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
